Ann: Further Research Coverage Initiated on CLINUVEL, page-6

I just googled clinuvel jefferies and about number 4 was a website thefly. There was a brief article that coverage has been initiated with a BUY rating and PRICE TARGET of $30. So a nice opening target with a hefty premium over the current price and I would guess it is all just based on EPP revenues with perhaps a tiny amount for the research pipeline. I have said before that Clinuvel is a victim of their own success, they have achieved consistent profitability on just the very small indication of EPP and it seems we are meant to believe that current share price manipulations represent some sort of fair value just when they are starting into the world's largest EPP market. Not in my opinion. I believe that the fact CUV are slow and steady with their build up means they have substantial data on safety, areas of effectiveness and a wealth of experience within the company and no value has been given to any of these factors at all and it does seem the accelerator is being pressed now (eg 23 or 25 US EPP centres in about 6 months, XP trials, PRENUMBRA). I think it is likely they will successfully roll their drug/s out to new indications and massive markets and I also look forward to some confirmation of this with the strategic update and the 2 new promised indications.
As for cash in this coming quarterly it is hard to gauge. I expect there will be some solid growth there over the last quarter and comparative quarterly from last year but not sure it will be a massive percentage (due to US lagging payments). I think the quarterly at the end of Jan will really show some big percentage increase in the order of approx. 100% so that should make a few people sit up and take some notice. I agree @Frogster they should give some guidance on US sales as it would be a nice boost. There just aren't many companies out there that will being having great revenue increases in the current financial year and Clinuvel is going to be one of them.
All IMO DYOR